#EULAR2020 #op0106 Cosentyx 150mg demonstrates clinical improvement in NrAxSpA Sx in Ph3 PREVENT 52wk study. Significant improvement in ASAS40, BASDAI50& ASdAS-CRP ID. MRI BME score significantly decreased (-1.68&-1.03 (no LD) vs -0.39 PBO) @RheumNow https://t.co/UX7mkJ8qMJ

#EULAR2020 #op0192 UK Biobank and IMPALA studies: metabolic body composition of PsA pts w/increased VAT,ectopic liver fat distribution & ⬆️ abdominal fat index associated w/increased risk of CHD&T2DM @RheumNow https://t.co/CwwAB2yUid

How often do you use MRI of peripheral joints for diagnosis or monitoring of PsA?

#EULAR2020 #op0182 delayed gadolinium-enhanced MRI study reveals proteoglycan loss in articulate cartilage in PsA associated w/severity of periarticular inflammation, synovitis &flexor tenosynovits but not bone erosion or prolypheration. @RheumNow https://t.co/ZJBDnZuYbB

#eular2020 #op0227 52 wk SEC vs ADA H2H EXCEED trial: Acr20 67.4%SEC vs 61.5%ADA. Better retention of SEC at 85.7% vs 76.3%ADA. SEC significantly outperforms in PASI90 (65.4 SEC be 43.2 ADA) @RheumNow https://t.co/M8UGydTFDF

#eular2020 #op0314 5 y drug-free remission (5DFR) is rare in early AxSpA: 17%pts from DESIR cohort reach 5DFR. Shorter disease duration (<1.3y), lower BASDAI&ASAS-CRP & less peripheral involv more likely to achieve DFR. Imaging and biological data did not predict DFR @RheumNow

New genome wide association study on anterior uveitis. Heritability for uveitis is 0.7, much greater than axSpA. Includes great data on genetic risk scores @ARVOiovs @AberdeenEpi @hteraG_senoJ https://t.co/gsX39YfrbN https://t.co/e8qBpL5xwy

• Genomewide Association Study of Acute Anterior Uveitis Identifies New Suscepti…

So maybe the optimal dose for psoriasis with UPA in PsA was tested? UPA works in PsA so another potential Rx for pts LB0001 @eular_org #EULAR2020 @RheumNow @CRASCRRheum @earlyarthritis https://t.co/GiT7H91umA

• https://twitter.com/drpnash/status/1268384558719762432

ENbrel works in long term for the few people left on the drug at 10 yrs with SpA. Enormous dropout. If you are still on Rx for a decade you are in the minority. Drop out of TNFi in SpA mirrors RA & PsA @RheumNow @eular_org @CRASCRRheum @earlyarthritis #EULAR2020 https://t.co/dLS2fw5uRP

• https://twitter.com/uptotate/status/1269358046150643713

Study in Norway reveals that the majority of the women w/ SpA were not treated with TNF inhibitors before or during pregnancy. Few on TNFi were continued on tx during pregnancy. #EULAR2020 @RheumNow https://t.co/t7B6pASeWQ https://t.co/BwU6RF5Qkn

• EULAR Abstract Archive

Sustained clinical response shown over the 10 yrs of this German study in r-axSpA and nr-axSpA pts treated with ETN. No new safety signals. Abstract #AB0660 #EULAR2020 @RheumNow https://t.co/KCMDyzHaSr https://t.co/yFSTgWqzBQ

• EULAR Abstract Archive

Switching TNFi to VDZ in pts IBD-related SpA associated w/ articular exacerbation of SpA in 1 out of 4 patients within the first 5 months. New-onset MEM is also observed in up to 15% of patients with IBD treated with VDZ. #EULAR2020 @RheumNow https://t.co/ZVjZC7hvxs https://t.co/d1RT3GzB2b

• EULAR Abstract Archive

#EULAR2020 #op0225 sub study of OPAL Balance: withdrawal of MTxdoes not negatively impact Tofa efficacy in PsA. At 6 mo deltaPASDAS 0.229 (0.079) for tofa mono & 0.q138 (0.081) for tofa+mtx. LFT elevation more common in combination arm @RheumNow https://t.co/NO1agViScD

Majority are correct. 1/3 of SAPHO meet PsA criteria esp if no osteitis @RheumNow @eular_org @CRASCRRheum @earlyarthritis #EULAR2020 https://t.co/B9wp8JxWpI

• https://twitter.com/janetbirdope/status/1268262664385462272

What % of SAPHO pts do you think have PsA? More if synovitis Less if osteitis #EULAR2020 @eular_org @RheumNow @CRASCRRheum AB0038